Omega-3 lifts adiponectin, the fat-tissue hormone, but leaves leptin alone

Body fat is not inert storage; it releases hormones called adipokines that play a role in metabolism, and two of the most studied are adiponectin and leptin. A large body of literature has reported beneficial effects of omega-3 fatty acid consumption on adipokine levels, which is part of the case often made for fish oil and related supplements. Recent clinical trial findings, however, have not agreed with one another. This systematic review and meta-analysis set out to resolve the disagreement by pooling every eligible trial and asking what omega-3 supplementation actually does to these hormones.

The researchers searched five major databases, Medline, Web of Science, Scopus, Embase and the Cochrane Library, from inception to August 2020, with no language restrictions, for randomised controlled trials of omega-3 fatty acid supplements reporting adipokine outcomes. Fifty-two trials involving 4,568 participants qualified. Because the trials measured hormones on different scales, results were combined as standardised mean differences using a random effects model. The two outcomes of interest were plasma adiponectin and leptin levels.

Omega-3 intake was associated with a significant but modest increase in plasma adiponectin, based on 43 trials covering 3,434 participants. The improvement was more favourable when people supplemented with more than 2000 mg daily for more than 10 weeks. Leptin was a different story: pooling the trials showed no significant effect whatsoever. The included trials also disagreed with each other considerably on the adiponectin result, which leaves the precise size of that effect uncertain even though its direction was consistent.

The analysis supports the older literature suggesting omega-3 intake benefits adiponectin levels, while pushing back on the idea that it moves leptin. The dose and duration pattern is a useful clue: shorter, lower-dose trials may explain why past findings looked inconsistent. The authors call for larger, well-designed trials, particularly to test whether leptin responds differently in specific diseases. What this review cannot say is how a modest adiponectin rise translates into outcomes people actually care about, such as weight or metabolic disease, because it measured hormones rather than health endpoints.

If you take an omega-3 supplement, this is a reason to expect any hormonal effect to be subtle and slow, showing up in trials only at higher doses taken beyond 10 weeks. It is not evidence that omega-3 changes appetite or weight, since leptin did not move and no health outcomes were assessed. Mostly this is a piece of honest sizing: a real but small shift in one favourable marker, and nothing on the other.